Speakers ****************************************************************************************** * ****************************************************************************************** ****************************************************************************************** * Keynote speakers ****************************************************************************************** *========================================================================================= * Martin Raditsch (DE) *========================================================================================= Position: CEO, Innovectis GmbH LinkedIn [ URL "https://de.linkedin.com/in/martin-raditsch-phd-rttp-61249053"] Martin Raditsch is CEO of Innovectis GmbH, responsible for the Universities Incubator “Goe Frankfurt am Main and is involved in a project venture fund . He also served until June202 of the pan-European association for professionals involved in knowledge transfer between u and industry (ASTP). He has 20 years of experience in international business development, and technology transfer in the pharma, med-tech, biotech and material sciences sector, ran industry to the public research sector. Mr. Raditsch holds a Ph.D. in Molecular Biology an as RTTP (registered technology transfer professional) by ATTP, the Global Alliance of Tech Professionals. Innovectis GmbH is the technology transfer company of the Goethe University *========================================================================================= * Edward van Wezel (NL) *========================================================================================= Position: Managing Partner, BioGeneration Ventures LinkedIn [ URL "https://nl.linkedin.com/in/edward-van-wezel-7363a41? challengeId=AQFCW0Zg0yzfJgAAAXN2WOeoDiT0ZDJ7QGiZK_-x0-32Y1ymnw6zfO3MbNFcbur30xlT6- ClkJX-1DmOFq4z630uJwZioLuzmg&submissionId=3df18600-9610-2416-f876-bd65cf50117e"] Edward van Wezel is a founder and Managing Partner at BioGeneration Ventures (BGV), Naarde Netherlands. He has extensive international expertise in pharma and biotech companies. Cur serves on the supervisory boards of Cristal Therapeutics, Synaffix, Staten Biotechnology, Biotechnology and Confo Therapeutics. He was a founding investor and board member of Acert company focussing on the development of a treatment for leukemia, that in 2016 was acquire for over $7 billion. Edward started his industrial career as a process engineer for Chiron Inc. He was a projec Johnson & Johnson responsible for product development projects in the oncology franchise, in corporate licensing activities. Since 2000, Edward gained experience as Chief Executive several biotech companies in the Netherlands. Edward van Wezel holds a MSc in chemistry fr of Utrecht, and a MSc in biochemical engineering from the Delft University of Technology. *========================================================================================= * Markéta Přenosilová (CZ) *========================================================================================= Position: Director of the Startups and Innovative Small and Medium-Sized Enterprises Divis CzechInvest LinkedIn [ URL "https://cz.linkedin.com/in/marketa-havlova"] Markéta Přenosilová holds a degree in public administration and regional development from University of Life Sciences. She has worked at CzechInvest since 2008, initially in the Re Development Department of the Investment Division. She was subsequently responsible for la CzechAccelerator project, which is focused on the internationalisation of start-ups. Marké Start-ups Department from 2016 to 2019. In 2020, she became the head of the Start-ups and Division, which covers a range of activities including support for the commercialisation o and their technological incubation and internationalisation, and working with potential in agency’s strategic sectors. ****************************************************************************************** * Panelists ****************************************************************************************** *========================================================================================= * Thomas Doppelberger *========================================================================================= Position: Director, Fraunhofer Venture  LinkedIn [ URL "https://www.linkedin.com/in/thomas-doppelberger-2b83706/de-de"] Thomas Doppelberger has been director of Fraunhofer Venture since 2001. He studied busines at the University of Augsburg with a focus on financial economics, taxation and controllin his first professional experience in an auditing company, then since 1998 as commercial co (calculation, application for national and EU-funded research projects) at the Fraunhofer- Fraunhofer Venture is responsible for the technology transfer via spin-offs of all 74 Frau as well as for the promotion and support of possible start-up topics of the Fraunhofer-Ges *========================================================================================= * Laura MacDonald *========================================================================================= Position: CEO ASTP, the Netherlands LinkedIn [ URL "https://www.linkedin.com/in/laura-macdonald-8956903/"] Laura MacDonald is responsible for managing the Dutch headquarters of this pan-European as of knowledge transfer professionals, with over 1000 members from almost 50 countries, acro academia. landscape. As well as ensuring the delivery of world class knowledge transfer tr conferences, she works with the Board and relevant departments of the European Commission strategies to enhance the European innovation ecosystem. The National (KT) Associations Ad (NAAC) of ASTP, provides European-wide KT insight and policy proposals to drive these stra graduate from the University of Glasgow, Laura’s professional life has concentrated on the transfer sector where she has gained extraordinary experience as the Head of Licensing at of Dundee then Edinburgh in Scotland (1992-2006) then at Leiden University Medical Centre University (2006-2016). *========================================================================================= * Tomáš Zima *========================================================================================= Position: Rector, Charles University Charles University website [ URL "https://cuni.cz/UKEN-255.html"] Prof. Tomáš Zima has been Rector of Charles University since 2014. He is the 508th Rector University and is also a member of the Czech Rectors Conference. He is also a member of th of the Czech Republic, the Czech Medical Academy, and the scientific boards of Masaryk Uni University of Economics, the Czech Chamber of Medicine and the Czech Health Research Counc member of the J.E. Purkyně Czech Medical Society, sits on commissions of professional orga the Czech Republic and abroad (ČSKB, ČSBMB, EFLM, IFCC, ESBRA) and the editorial boards of journals (Adiktologie, Folia Biologica, etc.). Since 1999 he has been the head of the Inst Biochemistry and Laboratory Diagnostics of the General University Hospital and of the 1st Medicine of Charles University. Zima graduated from the Charles University Faculty of General Medicine in 1990. From 1990 worked at the Institute of Medical Biochemistry of the 1st Faculty of Medicine of Charles has also worked at the 1st Clinic of Internal Medicine (and subsequently at the Nephrology General University Hospital and of the 1st Faculty of Medicine of Charles University). He credentialing in the fields of clinical chemistry, internal medicine and nephrology. In 19 associate professor (docent) at the 1st Faculty of Medicine of Charles University, and fiv was appointed professor of Charles University in medical chemistry and biochemistry. Prof. Zima is an honorary professor of the J.Y. Horbachevskyi State Medical University in honoris causa of Prešov University and of Uzhgorod University. From 2000–2003 he completed Prague Managerial School of the University of Economics. From 2005-2012 he was Dean of the Medicine of Charles University. *========================================================================================= * Petr Očko *========================================================================================= Position: Deputy Minister for Digitalisation and Innovation, Ministry of Industry and Trad LinkedIn [ URL "https://cz.linkedin.com/in/petrocko"] Petr Očko, born on April 22. 1976, graduated from Information Management and European Inte University of Economics in Prague and from Ph.D. studies of Information Economics at the F of Charles University in Prague. He started in 1998 in a small company that would now be l successful technology start up – the Globe Internet. As an expert in the European economic he has been working at the Ministry of Finance since 2001 on the EU Structural Funds, sinc as an advisor to the Deputy Minister of Finance for the financial market, and in 2006 he w the Government as a National Coordinator for the introduction of the euro. Since August 20 in the private sphere as an EU project coordinator for Telefónica O2. In 2009, he returned administration as Chief Executive Officer for EU Budget and EU Funds at the Ministry of Tr since August 2010 he served as Section Director for EU Funds, Research and Development at Industry and Trade, where he was in charge for key programs to support industrial research innovation and entrepreneurship. In 2012-2013 he was also in charge of the stabilization a of the CzechInvest business and investment support agency as its entrusted CEO. Since 2015 the Department of Financial Instruments and Project Management at the Ministry of Industry prepared mainly the National Innovation Fund project or the transformation of the Czech-Mo and Development Bank. In March 2016, he was appointed by the Government as chairman of the Technology Agency and successfully helped to develop support for applied research in key a Republic, including industry 4.0 and other major trends. ****************************************************************************************** * Afternoon speakers ****************************************************************************************** *========================================================================================= * Koen Verhoef *========================================================================================= Position: Head of TTO, Netherlands Cancer Institute LinkedIn [ URL "https://nl.linkedin.com/in/koen-verhoef-9510295"] Koen Verhoef is a molecular virologist by training, having obtained his PhD from the Unive Amsterdam in 1999. During his post-doctoral scientific career, he received two EMBO fellow allowed him to conduct research at the University of Heidelberg (1998-1999) and at Oxford (2000-2001). In 2001, Koen started as a technology transfer manager with MRC Technology (n the commercialisation company of the Medical Research Council in London, UK. In 2003, he m Netherlands where he founded the Technology Transfer Office at VU University Medical Centr which soon expanded its activities to the other Faculties of VU University. In April 2009, the head of the Technology Transfer Office of the Netherlands Cancer Institute [ URL "http tto/"] – Antoni van Leeuwenhoek hospital (NKI-AVL). Koen is an active member of ASTP [ URL www.astp4kt.eu/"] , the European professional association for Knowledge Transfer, and serv between 2010 and 2014. *========================================================================================= * Pierre Tangermann *========================================================================================= Position: CEO, PerioTrap Pharmaceuticals GmbH LinkedIn [ URL "https://de.linkedin.com/in/pierre-tangermann-b3078b6a? challengeId=AQHPTjYvEh2rmAAAAXN2aZH6sq97k6n4JNt2ay0HV7ilu9dK1Yy1pJSGrAtJTE9m5Z6PJspkgEYYLx P5617UX8Haw&submissionId=a0e6313d-9411-2416-5829-98fb29d4de52"] Pierre Tangermann and Mirko Bucholz are the CEOs of the German start-up company PerioTrap which was founded in December 2018. The company has developed a highly specific antibiotic periodontitis, making a major contribution to the risk of multi-resistant germs. Seven sci Halle and the Fraunhofer-Gesellschaft participated as founders in a research project which 2013 with EU funding. Based on the new insights, it was possible to develop an active ingr “double selective”. The developed active ingredient is now patented. Photo: ©TGZ Halle GmbH/Marco Warmuth *========================================================================================= * Mirko Buchholz *========================================================================================= Position: CEO, PerioTrap Pharmaceuticals GmbH LinkedIn [ URL "https://de.linkedin.com/in/mirko-buchholz-a694103b"] Pierre Tangermann and Mirko Bucholz are the CEOs of the German start-up company PerioTrap which was founded in December 2018. The company has developed a highly specific antibiotic periodontitis, making a major contribution to the risk of multi-resistant germs. Seven sci Halle and the Fraunhofer-Gesellschaft participated as founders in a research project which 2013 with EU funding. Based on the new insights, it was possible to develop an active ingr “double selective”. The developed active ingredient is now patented. Photo: ©TGZ Halle GmbH/Marco Warmuth *========================================================================================= * *========================================================================================= *========================================================================================= * Pavel Nevický *========================================================================================= Position: Co-Founder & CEO, MindPax (CZ/DE) LinkedIn [ URL "https://www.linkedin.com/in/pavel-nevicky-b02b145/"] *========================================================================================= * Jiri Schimer *========================================================================================= Position: Head of chemistry, DIANA Biotechnologies LinkedIn [ URL "https://www.linkedin.com/in/jiri-schimer-5b5a09167/?originalSubdomain=cz"] *========================================================================================= * Barbora Šumová *========================================================================================= Position: Member of the Board of LAM-X (Charles University Spin-of) LinkedIn [ URL "https://www.linkedin.com/in/barbora-%C5%A1umov%C3%A1-03b64589/"] Barbora Šumová is the Investment Manager at i&i Prague [ URL "https://www.iniprague.com/"] serves as a member of the Board of Directors of LAM-X [ URL "https://lam-x.tech/"] . In he connects the world of science and business. At i&i Prague, Barbora uses her analytical abi identify and assess new investment opportunities. She is actively involved in pre-seed/see negotiations, startups establishment and supervision of the company’s operational function obtained her Ph.D. degree in Immunology from the Charles University, Prague. For several y researched autoimmune diseases at the Friedrich-Alexander-Universität Erlangen-Nürnberg in *========================================================================================= * Moderators *========================================================================================= ------------------------------------------------------------------------------------------ Petr Kaiser ------------------------------------------------------------------------------------------ Position: Special Envoy for Science Diplomacy, The Ministry of Foreign Affairs of the Czec "https://www.mzv.cz/jnp/"] Petr Kaiser assumed the role of the Special Envoy for Science Diplomacy of the Czech Minis Affairs in July 2019 (however he was responsible for similar agenda from 2010 to 2016). Wi ministry's structure, he is embedded in Foreign Policy Analysis and Planning Department. H diplomat with more than twenty years of working experience. Before joining the diplomatic for some years as a researcher at the Academy of Sciences of the Czech Republic. In his ca responsible for advising the minister of foreign affairs in matters related to science dip develops projects for the Czech diplomatic service following the goals and objectives set strategies adopted by the Government and relevant institutions and bodies. He coordinates within the MFA mostly executed in partnership with other ministries, agencies, universitie centers. ------------------------------------------------------------------------------------------ Jaromír Zahrádka ------------------------------------------------------------------------------------------ Position: CEO, i&i Prague LinkedIn [ URL "https://cz.linkedin.com/in/jarom%C3%ADr-zahr%C3%A1dka-00937946"] Jaromír Zahrádka holds Ph.D. in Biochemistry from the Charles University in Prague and he master’s degree in Corporate Economics, Management and Enterprise valuation. Having the sc competence and economic background, he has developed a deep expertise in early-phase techn evaluation and market potential analysis for biotech R&D projects; furthermore, he is lect universities. Between 2012 and 2017, Jaromir worked as a Business development manager at I Tech Transfer office of IOCB Prague Institute, which is well known due to the development blockbuster Tenofovir TM, marketed by Gilead. In 2017, Jaromir became the CEO and co-found Prague, a unique investment and incubation company for early-phase academic spin-offs from (covering Medtech, Diagnostics and Drug discovery projects). Jaromir and his team in i&i P already supported the development of more than 7 deep-tech spin-offs (including Diana Biot LAM-X companies) and facilitated more than 10 out-licensing deals. Moreover, the total fun i&i Prague projects exceeded 40 mil EUR. i&i Prague projects are carefully selected from a pool consisting of more than 100 biotech projects originated at academic institutions from Poland, Germany, Austria, Slovakia and other countries. ------------------------------------------------------------------------------------------ Eva Janouškovcová ------------------------------------------------------------------------------------------ Position: CEO of Transfera.cz LinkedIn [ URL "https://cz.linkedin.com/in/eva-janou%C5%A1kovcov%C3%A1-40645a15? challengeId=AQHcVEziISMbsgAAAXN2nd0dzg17F8BlGk40U9nTUi_rUklgLp0OhMQqBN9sR7b9I7RSYHLW27FXNv b214-2416-40a5-4ec5cb173f1b"] Eva Janouškovcová graduated from the Faculty of Science at Masaryk University, majoring in She also holds a Ph.D. in Imunology and LL.M. from Corporate Law. She gained experience in transfer during her stay in the Office of Technology Transfer at McGill University, Montre She also attended many courses and certified trainings in technology transfer and intellec protection. She extends her extensive experience in solution and project management in the scientific research and technology transfer by participating in activities aimed at popula and research and cooperating on education development projects, innovation, research and d at regional, national and international level. She also gained significant experience in b management positions in private sector. In the TTO she is mainly responsible for protectio property and for support to the research community in this field; she negotiates research between MU researchers and application partners and organizes courses and trainings for in including technology transfer and intellectual property rights. ------------------------------------------------------------------------------------------ Hana Kosová ------------------------------------------------------------------------------------------ Position: Director of Centre for Knowledge and Technology Transfer of Charles University LinkedIn [ URL "https://www.linkedin.com/in/hana-kosova-10526619/"] Hana Kosová has been working with Charles University since 2011, starting as an independen consultant for pre-seed and proof of concept projects and later on building University Inn She has been part of the management team of the Centre for Knowledge and Technology Transf and in 2016 was appointed its director. She helped to shape the professional Czech nationa Transfera.cz and for 2015 - 2018 acted as its vice-president, she remains its board member has become a board member of the international knowledge and technology transfer professio ASTP. She was one of the team initiating and eventually in 2018 establishing a subsidiary University Innovations Prague, LLC for which she has been appointed the company´s Supervis